Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

"Heart attacks and strokes are among the most common ... Those in the medication group took a once-daily 14mg dose of oral semaglutide. Researchers found that oral semaglutide decreased the risk of ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...

Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

According to the researchers, the nonfatal heart attack reduction ... 2 McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes.